100130,1,Admission,O
100130,1,Date,O
100130,1,:,O
100130,1,[,O
100130,1,**2109-7-21**,O
100130,1,],O
100130,1,Discharge,O
100130,1,Date,O
100130,1,:,O
100130,1,[,O
100130,1,**2109-8-13**,O
100130,1,],O
100130,1,Date,O
100130,1,of,O
100130,1,Birth,O
100130,1,:,O
100130,1,[,O
100130,1,**2053-6-5**,O
100130,1,],O
100130,1,Sex,O
100130,1,:,O
100130,1,F,O
100130,1,Service,O
100130,1,:,O
100130,1,[,O
100130,1,**Doctor,O
100130,1,Last,O
100130,1,Name,O
100130,1,1181**,O
100130,1,],O
100130,1,MEDICINE,O
100130,1,HISTORY,O
100130,1,OF,O
100130,1,PRESENT,O
100130,1,ILLNESS,O
100130,1,:,O
100130,1,This,O
100130,1,is,O
100130,1,a,O
100130,1,56-year-old,O
100130,1,white,O
100130,1,female,O
100130,1,with,O
100130,1,a,O
100130,1,history,O
100130,1,of,O
100130,1,right,O
100130,1,frontal,O
100130,1,craniotomy,O
100130,1,on,O
100130,1,[,O
100130,1,**2109-7-1**,O
100130,1,],O
100130,1,",",O
100130,1,for,O
100130,1,a,O
100130,1,dysembryoplastic,O
100130,1,angioneural,O
100130,1,epithelial,O
100130,1,lesion,O
100130,1,with,O
100130,1,features,O
100130,1,of,O
100130,1,an,O
100130,1,oligodendroglioma,O
100130,1,who,O
100130,1,was,O
100130,1,started,O
100130,1,on,O
100130,1,Dilantin,B-Drug
100130,1,postoperatively,O
100130,1,for,O
100130,1,seizure,B-Reason
100130,1,prophylaxis,I-Reason
100130,1,and,O
100130,1,was,O
100130,1,subsequently,O
100130,1,developed,O
100130,1,eye,B-ADE
100130,1,discharge,I-ADE
100130,1,and,O
100130,1,was,O
100130,1,seen,O
100130,1,by,O
100130,1,an,O
100130,1,optometrist,O
100130,1,who,O
100130,1,treated,O
100130,1,it,O
100130,1,with,O
100130,1,sulfate,B-Drug
100130,1,ophthalmic,O
100130,1,drops,O
100130,1,.,O
100130,1,The,O
100130,1,patient,O
100130,1,then,O
100130,1,developed,O
100130,1,oral,B-ADE
100130,1,sores,I-ADE
100130,1,and,O
100130,1,rash,B-ADE
100130,1,in,O
100130,1,the,O
100130,1,chest,O
100130,1,the,O
100130,1,night,O
100130,1,before,O
100130,1,admission,O
100130,1,which,O
100130,1,rapidly,O
100130,1,spread,O
100130,1,to,O
100130,1,the,O
100130,1,face,O
100130,1,",",O
100130,1,trunk,O
100130,1,",",O
100130,1,and,O
100130,1,upper,O
100130,1,extremities,O
100130,1,within,O
100130,1,the,O
100130,1,last,O
100130,1,24,O
100130,1,hours,O
100130,1,.,O
100130,1,The,O
100130,1,patient,O
100130,1,was,O
100130,1,unable,O
100130,1,to,O
100130,1,eat,O
100130,1,secondary,O
100130,1,to,O
100130,1,mouth,O
100130,1,pain,O
100130,1,.,O
100130,1,She,O
100130,1,had,O
100130,1,fevers,B-ADE
100130,1,",",O
100130,1,weakness,B-ADE
100130,1,",",O
100130,1,and,O
100130,1,diarrhea,B-ADE
100130,1,.,O
100130,1,There,O
100130,1,were,O
100130,1,no,O
100130,1,genital,O
100130,1,the,O
100130,1,morning,O
100130,1,of,O
100130,1,[,O
100130,1,**7-20**,O
100130,1,],O
100130,1,.,O
100130,1,PAST,O
100130,1,MEDICAL,O
100130,1,HISTORY,O
100130,1,:,O
100130,1,1,O
100130,1,.,O
100130,1,Hypercholesterolemia,O
100130,1,.,O
100130,1,2,O
100130,1,.,O
100130,1,Benign,O
100130,1,right,O
100130,1,frontal,O
100130,1,cystic,O
100130,1,tumor,O
100130,1,status,O
100130,1,post,O
100130,1,right,O
100130,1,frontal,O
100130,1,craniotomy,O
100130,1,on,O
100130,1,[,O
100130,1,**2109-7-1**,O
100130,1,],O
100130,1,.,O
100130,1,ALLERGIES,O
100130,1,:,O
100130,1,NO,O
100130,1,KNOWN,O
100130,1,DRUG,O
100130,1,ALLERGIES,O
100130,1,.,O
100130,1,MEDICATIONS,O
100130,1,:,O
100130,1,Lipitor,B-Drug
100130,1,",",O
100130,1,Tylenol,B-Drug
100130,1,with,I-Drug
100130,1,Codeine,I-Drug
100130,1,",",O
100130,1,Dilantin,B-Drug
100130,1,",",O
100130,1,previously,O
100130,1,on,O
100130,1,Decadron,B-Drug
100130,1,q.i.d,O
100130,1,.,O
100130,1,tapered,O
100130,1,over,O
100130,1,one,O
100130,1,week,O
100130,1,and,O
100130,1,discontinued,O
100130,1,a,O
100130,1,week,O
100130,1,ago,O
100130,1,.,O
100130,1,SOCIAL,O
100130,1,HISTORY,O
100130,1,:,O
100130,1,The,O
100130,1,patient,O
100130,1,lives,O
100130,1,with,O
100130,1,her,O
100130,1,husband,O
100130,1,",",O
100130,1,daughter,O
100130,1,",",O
100130,1,and,O
100130,1,son,O
100130,1,.,O
100130,1,[,O
100130,1,**Name,O
100130,1,(,O
100130,1,NI,O
100130,1,),O
100130,1,**,O
100130,1,],O
100130,1,smoking,O
100130,1,or,O
100130,1,ethanol,O
100130,1,use,O
100130,1,history,O
100130,1,.,O
100130,1,PHYSICAL,O
100130,1,EXAMINATION,O
100130,1,:,O
100130,1,Vital,O
100130,1,signs,O
100130,1,:,O
100130,1,T-max,O
100130,1,104.3,O
100130,1,?,O
100130,1,?,O
100130,1,?,O
100130,1,?,O
100130,1,?,O
100130,1,?,O
100130,1,",",O
100130,1,currently,O
100130,1,100.8,O
100130,1,?,O
100130,1,?,O
100130,1,?,O
100130,1,?,O
100130,1,?,O
100130,1,?,O
100130,1,",",O
100130,1,heart,O
100130,1,rate,O
100130,1,107-110,O
100130,1,",",O
100130,1,blood,O
100130,1,pressure,O
100130,1,110/27,O
100130,1,",",O
100130,1,respirations,O
100130,1,15-20,O
100130,1,",",O
100130,1,oxygen,O
100130,1,saturation,O
100130,1,98,O
100130,1,%,O
100130,1,on,O
100130,1,room,O
100130,1,air,O
100130,1,.,O
100130,1,General,O
100130,1,:,O
100130,1,The,O
100130,1,patient,O
100130,1,was,O
100130,1,an,O
100130,1,alert,O
100130,1,",",O
100130,1,ill-appearing,O
100130,1,woman,O
100130,1,with,O
100130,1,postsurgical,O
100130,1,occiput,O
100130,1,.,O
100130,2,Head,O
100130,2,and,O
100130,2,neck,O
100130,2,:,O
100130,2,Injected,O
100130,2,conjunctivae,O
100130,2,",",O
100130,2,greenish,O
100130,2,ocular,O
100130,2,discharge,O
100130,2,",",O
100130,2,ulcerative,O
100130,2,oral,O
100130,2,lesions,O
100130,2,.,O
100130,2,Cardiovascular,O
100130,2,:,O
100130,2,Regular,O
100130,2,rhythm,O
100130,2,.,O
100130,2,Rapid,O
100130,2,rate,O
100130,2,.,O
100130,2,No,O
100130,2,murmurs,O
100130,2,.,O
100130,2,Pulmonary,O
100130,2,:,O
100130,2,Clear,O
100130,2,to,O
100130,2,auscultation,O
100130,2,bilaterally,O
100130,2,.,O
100130,2,Abdomen,O
100130,2,:,O
100130,2,Normoactive,O
100130,2,bowel,O
100130,2,sounds,O
100130,2,.,O
100130,2,Soft,O
100130,2,",",O
100130,2,nontender,O
100130,2,",",O
100130,2,nondistended,O
100130,2,.,O
100130,2,Extremities,O
100130,2,:,O
100130,2,No,O
100130,2,edema,O
100130,2,.,O
100130,2,Skin,O
100130,2,:,O
100130,2,Diffuse,O
100130,2,erythema,O
100130,2,and,O
100130,2,pustules,O
100130,2,on,O
100130,2,the,O
100130,2,face,O
100130,2,.,O
100130,2,Patulous,O
100130,2,pustules,O
100130,2,on,O
100130,2,the,O
100130,2,chest,O
100130,2,",",O
100130,2,back,O
100130,2,",",O
100130,2,and,O
100130,2,proximal,O
100130,2,upper,O
100130,2,extremities,O
100130,2,.,O
100130,2,GU,O
100130,2,:,O
100130,2,No,O
100130,2,genital,O
100130,2,lesions,O
100130,2,.,O
100130,2,LABORATORY,O
100130,2,DATA,O
100130,2,:,O
100130,2,Hematocrit,O
100130,2,34.1,O
100130,2,",",O
100130,2,WBC,O
100130,2,10.3,O
100130,2,",",O
100130,2,platelet,O
100130,2,count,O
100130,2,"291,000",O
100130,2,",",O
100130,2,differential,O
100130,2,of,O
100130,2,87,O
100130,2,neutrophils,O
100130,2,",",O
100130,2,0,O
100130,2,bands,O
100130,2,;,O
100130,2,sodium,O
100130,2,133,O
100130,2,",",O
100130,2,potassium,O
100130,2,3.8,O
100130,2,",",O
100130,2,chloride,O
100130,2,93,O
100130,2,",",O
100130,2,CO2,O
100130,2,21,O
100130,2,",",O
100130,2,BUN,O
100130,2,17,O
100130,2,",",O
100130,2,creatinine,O
100130,2,0.9,O
100130,2,",",O
100130,2,glucose,O
100130,2,121,O
100130,2,;,O
100130,2,ALT,O
100130,2,39,O
100130,2,",",O
100130,2,AST,O
100130,2,42,O
100130,2,",",O
100130,2,LDH,O
100130,2,434,O
100130,2,",",O
100130,2,amylase,O
100130,2,63,O
100130,2,",",O
100130,2,albumin,O
100130,2,3.4,O
100130,2,",",O
100130,2,total,O
100130,2,bilirubin,O
100130,2,0.3,O
100130,2,;,O
100130,2,urinalysis,O
100130,2,with,O
100130,2,positive,O
100130,2,ketones,O
100130,2,",",O
100130,2,negative,O
100130,2,nitrites,O
100130,2,;,O
100130,2,urine,O
100130,2,culture,O
100130,2,pending,O
100130,2,;,O
100130,2,blood,O
100130,2,cultures,O
100130,2,times,O
100130,2,two,O
100130,2,pending,O
100130,2,;,O
100130,2,conjunctival,O
100130,2,culture,O
100130,2,pending,O
100130,2,.,O
100130,2,HOSPITAL,O
100130,2,COURSE,O
100130,2,:,O
100130,2,Given,O
100130,2,the,O
100130,2,patient,O
100130,2,'s,O
100130,2,severe,O
100130,2,exfoliative,O
100130,2,skin,O
100130,2,involvement,O
100130,2,with,O
100130,2,rapid,O
100130,2,progression,O
100130,2,and,O
100130,2,extensive,O
100130,2,involvement,O
100130,2,of,O
100130,2,the,O
100130,2,body,O
100130,2,",",O
100130,2,she,O
100130,2,was,O
100130,2,admitted,O
100130,2,to,O
100130,2,the,O
100130,2,Medical,O
100130,2,Intensive,O
100130,2,Care,O
100130,2,Unit,O
100130,2,for,O
100130,2,close,O
100130,2,monitoring,O
100130,2,.,O
100130,2,She,O
100130,2,was,O
100130,2,started,O
100130,2,on,O
100130,2,prophylactic,O
100130,2,Oxacillin,B-Drug
100130,2,to,O
100130,2,cover,O
100130,2,skin,O
100130,2,flora,O
100130,2,",",O
100130,2,and,O
100130,2,Dermatology,O
100130,2,was,O
100130,2,consulted,O
100130,2,along,O
100130,2,with,O
100130,2,Neurology,O
100130,2,and,O
100130,2,Ophthalmology,O
100130,2,for,O
100130,2,the,O
100130,2,ophthalmic,B-Reason
100130,2,involvement,I-Reason
100130,2,.,O
100130,2,The,O
100130,2,patient,O
100130,2,'s,O
100130,2,course,O
100130,2,in,O
100130,2,the,O
100130,2,Intensive,O
100130,2,Care,O
100130,2,Unit,O
100130,2,was,O
100130,2,uneventful,O
100130,2,",",O
100130,2,and,O
100130,2,she,O
100130,2,was,O
100130,2,discharged,O
100130,2,to,O
100130,2,the,O
100130,2,floor,O
100130,2,with,O
100130,2,very,O
100130,2,close,O
100130,2,monitoring,O
100130,2,which,O
100130,2,included,O
100130,2,q.1,O
100130,2,hour,O
100130,2,Pred,B-Drug
100130,2,Forte,I-Drug
100130,2,application,O
100130,2,to,O
100130,2,the,O
100130,2,eye,O
100130,2,and,O
100130,2,close,O
100130,2,consultation,O
100130,2,with,O
100130,2,Ophthalmology,O
100130,2,.,O
100130,2,With,O
100130,2,regard,O
100130,2,to,O
100130,2,her,O
100130,2,skin,O
100130,2,lesions,O
100130,2,",",O
100130,2,they,O
100130,2,continued,O
100130,2,exfoliate,O
100130,2,over,O
100130,2,the,O
100130,2,next,O
100130,2,couple,O
100130,2,of,O
100130,2,days,O
100130,2,",",O
100130,2,and,O
100130,2,her,O
100130,2,skin,O
100130,2,care,O
100130,2,included,O
100130,2,frequent,O
100130,2,Vaseline,B-Drug
100130,2,hydrated,I-Drug
100130,2,petroleum,I-Drug
100130,2,application,O
100130,2,to,O
100130,2,decrease,B-Reason
100130,2,insensible,I-Reason
100130,2,losses,I-Reason
100130,2,.,O
100130,2,The,O
100130,2,patient's,O
100130,2,intake,O
100130,2,and,O
100130,2,output,O
100130,2,were,O
100130,2,closely,O
100130,2,monitored,O
100130,3,and,O
100130,3,replaced,O
100130,3,appropriately,O
100130,3,;,O
100130,3,however,O
100130,3,",",O
100130,3,the,O
100130,3,intensive,O
100130,3,nursing,O
100130,3,care,O
100130,3,requirement,O
100130,3,made,O
100130,3,it,O
100130,3,difficult,O
100130,3,for,O
100130,3,the,O
100130,3,patient,O
100130,3,to,O
100130,3,receive,O
100130,3,adequate,O
100130,3,on,O
100130,3,the,O
100130,3,floor,O
100130,3,",",O
100130,3,and,O
100130,3,therefore,O
100130,3,",",O
100130,3,she,O
100130,3,was,O
100130,3,transferred,O
100130,3,to,O
100130,3,the,O
100130,3,Medical,O
100130,3,Intensive,O
100130,3,Care,O
100130,3,Unit,O
100130,3,again,O
100130,3,for,O
100130,3,frequent,O
100130,3,ophthalmic,O
100130,3,applications,O
100130,3,and,O
100130,3,skin,O
100130,3,care,O
100130,3,.,O
100130,3,While,O
100130,3,in,O
100130,3,the,O
100130,3,MICU,O
100130,3,",",O
100130,3,the,O
100130,3,patient,O
100130,3,continued,O
100130,3,to,O
100130,3,have,O
100130,3,meticulous,O
100130,3,skin,O
100130,3,care,O
100130,3,and,O
100130,3,eye,O
100130,3,care,O
100130,3,.,O
100130,3,The,O
100130,3,skin,O
100130,3,lesions,O
100130,3,continued,O
100130,3,to,O
100130,3,desquamate,O
100130,3,and,O
100130,3,exfoliate,O
100130,3,which,O
100130,3,is,O
100130,3,the,O
100130,3,natural,O
100130,3,progression,O
100130,3,of,O
100130,3,this,O
100130,3,disease,O
100130,3,.,O
100130,3,She,O
100130,3,began,O
100130,3,to,O
100130,3,have,O
100130,3,involvement,O
100130,3,of,O
100130,3,the,O
100130,3,genital,O
100130,3,area,O
100130,3,with,O
100130,3,continued,O
100130,3,desquamation,O
100130,3,of,O
100130,3,the,O
100130,3,exfoliative,O
100130,3,lesions,O
100130,3,.,O
100130,3,Her,O
100130,3,course,O
100130,3,in,O
100130,3,the,O
100130,3,Intensive,O
100130,3,Care,O
100130,3,Unit,O
100130,3,within,O
100130,3,the,O
100130,3,next,O
100130,3,8-10,O
100130,3,days,O
100130,3,was,O
100130,3,a,O
100130,3,slow,O
100130,3,but,O
100130,3,gradual,O
100130,3,improvement,O
100130,3,from,O
100130,3,a,O
100130,3,dermatologic,O
100130,3,and,O
100130,3,ophthalmologic,O
100130,3,standpoint,O
100130,3,.,O
100130,3,From,O
100130,3,a,O
100130,3,cardiovascular,O
100130,3,standpoint,O
100130,3,",",O
100130,3,she,O
100130,3,was,O
100130,3,in,O
100130,3,sinus,O
100130,3,tachycardia,O
100130,3,which,O
100130,3,was,O
100130,3,felt,O
100130,3,to,O
100130,3,be,O
100130,3,secondary,O
100130,3,to,O
100130,3,her,O
100130,3,[,O
100130,3,**Doctor,O
100130,3,Last,O
100130,3,Name,O
100130,3,**,O
100130,3,],O
100130,3,-,O
100130,3,[,O
100130,3,**Location,O
100130,3,(,O
100130,3,un,O
100130,3,),O
100130,3,**,O
100130,3,],O
100130,3,syndrome,O
100130,3,leading,O
100130,3,to,O
100130,3,dehydration,O
100130,3,and,O
100130,3,insensible,O
100130,3,fluid,O
100130,3,losses,O
100130,3,.,O
100130,3,While,O
100130,3,in,O
100130,3,the,O
100130,3,Intensive,O
100130,3,Care,O
100130,3,Unit,O
100130,3,",",O
100130,3,she,O
100130,3,was,O
100130,3,also,O
100130,3,found,O
100130,3,to,O
100130,3,be,O
100130,3,mildly,O
100130,3,hypoxic,O
100130,3,which,O
100130,3,is,O
100130,3,likely,O
100130,3,secondary,O
100130,3,to,O
100130,3,atelectasis,O
100130,3,because,O
100130,3,of,O
100130,3,the,O
100130,3,patient,O
100130,3,'s,O
100130,3,immobility,O
100130,3,.,O
100130,3,Lower,O
100130,3,extremity,O
100130,3,Dopplers,O
100130,3,were,O
100130,3,also,O
100130,3,done,O
100130,3,",",O
100130,3,and,O
100130,3,no,O
100130,3,deep,O
100130,3,venous,O
100130,3,thromboses,O
100130,3,were,O
100130,3,found,O
100130,3,.,O
100130,3,From,O
100130,3,and,O
100130,3,Infectious,O
100130,3,Disease,O
100130,3,standpoint,O
100130,3,",",O
100130,3,the,O
100130,3,patient,O
100130,3,was,O
100130,3,started,O
100130,3,on,O
100130,3,intravenous,O
100130,3,Oxacillin,B-Drug
100130,3,empirically,O
100130,3,.,O
100130,3,Blood,O
100130,3,cultures,O
100130,3,on,O
100130,3,the,O
100130,3,5th,O
100130,3,was,O
100130,3,with,O
100130,3,no,O
100130,3,growth,O
100130,3,times,O
100130,3,two,O
100130,3,;,O
100130,3,however,O
100130,3,",",O
100130,3,one,O
100130,3,bottle,O
100130,3,from,O
100130,3,her,O
100130,3,PICC,O
100130,3,line,O
100130,3,grew,O
100130,3,out,O
100130,3,gram-positive,O
100130,3,cocci,O
100130,3,on,O
100130,3,[,O
100130,3,**7-27**,O
100130,3,],O
100130,3,.,O
100130,3,She,O
100130,3,was,O
100130,3,started,O
100130,3,on,O
100130,3,a,O
100130,3,course,O
100130,3,of,O
100130,3,Vancomycin,B-Drug
100130,3,.,O
100130,3,Subsequently,O
100130,3,the,O
100130,3,organism,O
100130,3,was,O
100130,3,found,O
100130,3,to,O
100130,3,be,O
100130,3,CNS,O
100130,3,with,O
100130,3,Corynebacterium,O
100130,3,",",O
100130,3,and,O
100130,3,Vancomycin,B-Drug
100130,3,was,O
100130,3,discontinued,O
100130,3,prior,O
100130,3,to,O
100130,3,transfer,O
100130,3,to,O
100130,3,the,O
100130,3,floor,O
100130,3,on,O
100130,3,[,O
100130,3,**8-5**,O
100130,3,],O
100130,3,.,O
100130,3,The,O
100130,3,patient,O
100130,3,'s,O
100130,3,course,O
100130,3,on,O
100130,3,the,O
100130,3,floor,O
100130,3,was,O
100130,3,uncomplicated,O
100130,3,with,O
100130,3,continued,O
100130,3,improvement,O
100130,3,.,O
100130,3,Dermatology,O
100130,3,:,O
100130,3,The,O
100130,4,patient,O
100130,4,",",O
100130,4,as,O
100130,4,indicated,O
100130,4,",",O
100130,4,improved,O
100130,4,dramatically,O
100130,4,from,O
100130,4,her,O
100130,4,presentation,O
100130,4,to,O
100130,4,the,O
100130,4,time,O
100130,4,of,O
100130,4,discharge,O
100130,4,.,O
100130,4,Her,O
100130,4,exfoliative,O
100130,4,lesions,O
100130,4,healed,O
100130,4,over,O
100130,4,the,O
100130,4,course,O
100130,4,of,O
100130,4,this,O
100130,4,admission,O
100130,4,.,O
100130,4,Her,O
100130,4,skin,O
100130,4,care,O
100130,4,requirements,O
100130,4,decreased,O
100130,4,to,O
100130,4,Petroleum,B-Drug
100130,4,jelly,I-Drug
100130,4,twice,O
100130,4,a,O
100130,4,day,O
100130,4,at,O
100130,4,the,O
100130,4,time,O
100130,4,of,O
100130,4,discharge,O
100130,4,.,O
100130,4,She,O
100130,4,was,O
100130,4,able,O
100130,4,to,O
100130,4,take,O
100130,4,in,O
100130,4,oral,O
100130,4,foot,O
100130,4,without,O
100130,4,problems,O
100130,4,.,O
100130,4,Ophthalmology,O
100130,4,:,O
100130,4,The,O
100130,4,patient,O
100130,4,'s,O
100130,4,eye,O
100130,4,care,O
100130,4,requirement,O
100130,4,improved,O
100130,4,markedly,O
100130,4,.,O
100130,4,She,O
100130,4,was,O
100130,4,able,O
100130,4,to,O
100130,4,open,O
100130,4,her,O
100130,4,eyes,O
100130,4,and,O
100130,4,use,O
100130,4,her,O
100130,4,vision,O
100130,4,without,O
100130,4,significant,O
100130,4,problems,O
100130,4,at,O
100130,4,the,O
100130,4,time,O
100130,4,of,O
100130,4,discharge,O
100130,4,.,O
100130,4,Her,O
100130,4,Pred,B-Drug
100130,4,Forte,I-Drug
100130,4,was,O
100130,4,discontinued,O
100130,4,on,O
100130,4,the,O
100130,4,day,O
100130,4,of,O
100130,4,discharge,O
100130,4,",",O
100130,4,and,O
100130,4,she,O
100130,4,is,O
100130,4,to,O
100130,4,have,O
100130,4,follow-up,O
100130,4,with,O
100130,4,Ophthalmology,O
100130,4,a,O
100130,4,couple,O
100130,4,of,O
100130,4,days,O
100130,4,after,O
100130,4,discharge,O
100130,4,.,O
100130,4,Fluid,O
100130,4,",",O
100130,4,electrolytes,O
100130,4,",",O
100130,4,and,O
100130,4,nutrition,O
100130,4,:,O
100130,4,On,O
100130,4,admission,O
100130,4,the,O
100130,4,patient,O
100130,4,was,O
100130,4,begun,O
100130,4,on,O
100130,4,TPN,O
100130,4,for,O
100130,4,nutritional,O
100130,4,support,O
100130,4,.,O
100130,4,As,O
100130,4,the,O
100130,4,patient,O
100130,4,improved,O
100130,4,from,O
100130,4,a,O
100130,4,medical,O
100130,4,perspective,O
100130,4,",",O
100130,4,her,O
100130,4,TPN,O
100130,4,was,O
100130,4,weaned,O
100130,4,",",O
100130,4,and,O
100130,4,at,O
100130,4,the,O
100130,4,time,O
100130,4,of,O
100130,4,discharge,O
100130,4,",",O
100130,4,the,O
100130,4,patient,O
100130,4,was,O
100130,4,taking,O
100130,4,adequate,O
100130,4,p.o,O
100130,4,.,O
100130,4,with,O
100130,4,supplementation,O
100130,4,of,O
100130,4,Boost,B-Drug
100130,4,.,O
100130,4,Infectious,B-Reason
100130,4,Disease,I-Reason
100130,4,:,O
100130,4,At,O
100130,4,the,O
100130,4,time,O
100130,4,of,O
100130,4,admission,O
100130,4,",",O
100130,4,she,O
100130,4,was,O
100130,4,started,O
100130,4,on,O
100130,4,empiric,O
100130,4,antibiotics,B-Drug
100130,4,and,O
100130,4,placed,O
100130,4,on,O
100130,4,contact,O
100130,4,precautions,O
100130,4,secondary,O
100130,4,to,O
100130,4,her,O
100130,4,extensive,O
100130,4,skin,O
100130,4,lesions,O
100130,4,;,O
100130,4,however,O
100130,4,",",O
100130,4,as,O
100130,4,the,O
100130,4,patient,O
100130,4,improved,O
100130,4,throughout,O
100130,4,the,O
100130,4,course,O
100130,4,of,O
100130,4,this,O
100130,4,admission,O
100130,4,",",O
100130,4,contact,O
100130,4,precautions,O
100130,4,were,O
100130,4,discontinued,O
100130,4,",",O
100130,4,and,O
100130,4,the,O
100130,4,patient,O
100130,4,was,O
100130,4,discharged,O
100130,4,home,O
100130,4,with,O
100130,4,services,O
100130,4,.,O
100130,4,Cardiology/Pulmonology,O
100130,4,:,O
100130,4,The,O
100130,4,patient,O
100130,4,was,O
100130,4,tachycardiac,O
100130,4,throughout,O
100130,4,this,O
100130,4,admission,O
100130,4,which,O
100130,4,was,O
100130,4,attributed,O
100130,4,to,O
100130,4,her,O
100130,4,fluid,O
100130,4,losses,O
100130,4,secondary,O
100130,4,to,O
100130,4,[,O
100130,4,**Doctor,O
100130,4,Last,O
100130,4,Name,O
100130,4,**,O
100130,4,],O
100130,4,-,O
100130,4,[,O
100130,4,**Location,O
100130,4,(,O
100130,4,un,O
100130,4,),O
100130,4,**,O
100130,4,],O
100130,4,syndrome,O
100130,4,;,O
100130,4,however,O
100130,4,",",O
100130,4,given,O
100130,4,the,O
100130,4,patient,O
100130,4,'s,O
100130,4,immobility,O
100130,4,throughout,O
100130,4,the,O
100130,4,course,O
100130,4,of,O
100130,4,this,O
100130,4,admission,O
100130,4,",",O
100130,4,a,O
100130,4,CT,O
100130,4,angiogram,O
100130,4,was,O
100130,4,performed,O
100130,4,to,O
100130,4,evaluate,O
100130,4,for,O
100130,4,possible,O
100130,4,pulmonary,O
100130,4,embolism,O
100130,4,",",O
100130,4,and,O
100130,4,none,O
100130,4,were,O
100130,4,found,O
100130,4,.,O
100130,4,Neurology,O
100130,4,:,O
100130,4,The,O
100130,4,patient,O
100130,4,has,O
100130,4,a,O
100130,4,history,O
100130,4,of,O
100130,4,cystic,B-Reason
100130,4,tumor,I-Reason
100130,4,status,I-Reason
100130,4,post,O
100130,4,resection,O
100130,4,in,O
100130,4,[,O
100130,4,**Month,O
100130,4,(,O
100130,5,only,O
100130,5,),O
100130,5,205**,O
100130,5,],O
100130,5,of,O
100130,5,this,O
100130,5,year,O
100130,5,and,O
100130,5,was,O
100130,5,started,O
100130,5,on,O
100130,5,prophylactic,O
100130,5,Dilantin,B-Drug
100130,5,leading,O
100130,5,to,O
100130,5,presumed,O
100130,5,[,O
100130,5,**Doctor,O
100130,5,Last,O
100130,5,Name,O
100130,5,**,O
100130,5,],O
100130,5,-,O
100130,5,[,O
100130,5,**Location,O
100130,5,(,O
100130,5,un,O
100130,5,),O
100130,5,**,O
100130,5,],O
100130,5,syndrome,O
100130,5,.,O
100130,5,At,O
100130,5,the,O
100130,5,time,O
100130,5,of,O
100130,5,this,O
100130,5,admission,O
100130,5,",",O
100130,5,the,O
100130,5,patient,O
100130,5,'s,O
100130,5,Dilantin,B-Drug
100130,5,was,O
100130,5,discontinued,O
100130,5,",",O
100130,5,and,O
100130,5,no,O
100130,5,other,O
100130,5,anticonvulsants,B-Drug
100130,5,were,O
100130,5,started,O
100130,5,",",O
100130,5,given,O
100130,5,the,O
100130,5,patient,O
100130,5,'s,O
100130,5,risk,O
100130,5,of,O
100130,5,seizures,O
100130,5,several,O
100130,5,weeks,O
100130,5,after,O
100130,5,her,O
100130,5,surgery,O
100130,5,was,O
100130,5,unlikely,O
100130,5,.,O
100130,5,This,O
100130,5,decision,O
100130,5,was,O
100130,5,made,O
100130,5,with,O
100130,5,the,O
100130,5,support,O
100130,5,of,O
100130,5,her,O
100130,5,neurosurgeon,O
100130,5,",",O
100130,5,Dr.,O
100130,5,[,O
100130,5,**Last,O
100130,5,Name,O
100130,5,(,O
100130,5,STitle,O
100130,5,),O
100130,5,**,O
100130,5,],O
100130,5,[,O
100130,5,**Last,O
100130,5,Name,O
100130,5,(,O
100130,5,NamePattern4,O
100130,5,),O
100130,5,1338**,O
100130,5,],O
100130,5,.,O
100130,5,Five,O
100130,5,days,O
100130,5,before,O
100130,5,discharge,O
100130,5,",",O
100130,5,the,O
100130,5,patient,O
100130,5,did,O
100130,5,have,O
100130,5,a,O
100130,5,syncopal,O
100130,5,event,O
100130,5,while,O
100130,5,in,O
100130,5,the,O
100130,5,bathroom,O
100130,5,showering,O
100130,5,with,O
100130,5,the,O
100130,5,help,O
100130,5,of,O
100130,5,a,O
100130,5,nursing,O
100130,5,aide,O
100130,5,.,O
100130,5,The,O
100130,5,likely,O
100130,5,etiology,O
100130,5,of,O
100130,5,this,O
100130,5,is,O
100130,5,orthostatic,O
100130,5,hypotension,O
100130,5,from,O
100130,5,her,O
100130,5,fluid,O
100130,5,losses,O
100130,5,;,O
100130,5,however,O
100130,5,",",O
100130,5,given,O
100130,5,the,O
100130,5,patient,O
100130,5,'s,O
100130,5,neurologic,O
100130,5,history,O
100130,5,",",O
100130,5,Neurology,O
100130,5,was,O
100130,5,consulted,O
100130,5,to,O
100130,5,evaluate,O
100130,5,for,O
100130,5,possible,O
100130,5,seizure,O
100130,5,.,O
100130,5,Neurology,O
100130,5,'s,O
100130,5,recommendations,O
100130,5,were,O
100130,5,to,O
100130,5,obtain,O
100130,5,a,O
100130,5,repeat,O
100130,5,CT,O
100130,5,scan,O
100130,5,which,O
100130,5,was,O
100130,5,unchanged,O
100130,5,from,O
100130,5,previous,O
100130,5,showing,O
100130,5,a,O
100130,5,right,O
100130,5,frontal,O
100130,5,lobe,O
100130,5,extra-axial,O
100130,5,hypodensity,O
100130,5,which,O
100130,5,was,O
100130,5,stable,O
100130,5,.,O
100130,5,They,O
100130,5,also,O
100130,5,recommended,O
100130,5,repeat,O
100130,5,MR,O
100130,5,imaging,O
100130,5,which,O
100130,5,was,O
100130,5,again,O
100130,5,unremarkable,O
100130,5,except,O
100130,5,for,O
100130,5,a,O
100130,5,stable,O
100130,5,extra-axial,O
100130,5,lesion,O
100130,5,noted,O
100130,5,on,O
100130,5,CT,O
100130,5,scan,O
100130,5,.,O
100130,5,Neurology,O
100130,5,therefore,O
100130,5,agrees,O
100130,5,with,O
100130,5,the,O
100130,5,primary,O
100130,5,team,O
100130,5,that,O
100130,5,the,O
100130,5,syncopal,O
100130,5,event,O
100130,5,was,O
100130,5,likely,O
100130,5,secondary,O
100130,5,to,O
100130,5,a,O
100130,5,vasovagal,O
100130,5,reaction,O
100130,5,.,O
100130,5,A,O
100130,5,follow-up,O
100130,5,MR,O
100130,5,scan,O
100130,5,would,O
100130,5,be,O
100130,5,recommended,O
100130,5,with,O
100130,5,gadolinium,O
100130,5,to,O
100130,5,evaluate,O
100130,5,for,O
100130,5,the,O
100130,5,presence,O
100130,5,of,O
100130,5,residual,O
100130,5,tumor,O
100130,5,.,O
100130,5,This,O
100130,5,can,O
100130,5,be,O
100130,5,done,O
100130,5,as,O
100130,5,an,O
100130,5,outpatient,O
100130,5,with,O
100130,5,Dr.,O
100130,5,[,O
100130,5,**Last,O
100130,5,Name,O
100130,5,(,O
100130,5,STitle,O
100130,5,),O
100130,5,1338**,O
100130,5,],O
100130,5,.,O
100130,5,Rehabilitation,O
100130,5,:,O
100130,5,The,O
100130,5,patient,O
100130,5,throughout,O
100130,5,this,O
100130,5,admission,O
100130,5,worked,O
100130,5,with,O
100130,5,our,O
100130,5,physical,O
100130,5,therapy,O
100130,5,people,O
100130,5,and,O
100130,5,continued,O
100130,5,to,O
100130,5,improve,O
100130,5,with,O
100130,5,regard,O
100130,5,to,O
100130,5,range,O
100130,5,of,O
100130,5,motion,O
100130,5,and,O
100130,5,strength,O
100130,5,in,O
100130,5,the,O
100130,5,upper,O
100130,5,and,O
100130,5,lower,O
100130,5,extremities,O
100130,5,",",O
100130,5,and,O
100130,5,by,O
100130,5,the,O
100130,5,time,O
100130,5,of,O
100130,5,discharge,O
100130,5,",",O
100130,5,she,O
100130,5,was,O
100130,5,ambulating,O
100130,5,throughout,O
100130,5,the,O
100130,5,[,O
100130,6,**Doctor,O
100130,6,Last,O
100130,6,Name,O
100130,6,**,O
100130,6,],O
100130,6,and,O
100130,6,around,O
100130,6,the,O
100130,6,hospital,O
100130,6,without,O
100130,6,problems,O
100130,6,.,O
100130,6,She,O
100130,6,was,O
100130,6,therefore,O
100130,6,discharged,O
100130,6,home,O
100130,6,without,O
100130,6,need,O
100130,6,for,O
100130,6,Physical,O
100130,6,Therapy,O
100130,6,Services,O
100130,6,.,O
100130,6,At,O
100130,6,the,O
100130,6,time,O
100130,6,of,O
100130,6,discharge,O
100130,6,",",O
100130,6,the,O
100130,6,patient,O
100130,6,has,O
100130,6,markedly,O
100130,6,improved,O
100130,6,from,O
100130,6,her,O
100130,6,initial,O
100130,6,presentation,O
100130,6,and,O
100130,6,is,O
100130,6,to,O
100130,6,be,O
100130,6,discharged,O
100130,6,home,O
100130,6,with,O
100130,6,nursing,O
100130,6,assistance,O
100130,6,.,O
100130,6,DISCHARGE,O
100130,6,STATUS,O
100130,6,:,O
100130,6,Markedly,O
100130,6,improved,O
100130,6,.,O
100130,6,DISCHARGE,O
100130,6,DIAGNOSIS,O
100130,6,:,O
100130,6,1,O
100130,6,.,O
100130,6,[,O
100130,6,**Doctor,O
100130,6,Last,O
100130,6,Name,O
100130,6,**,O
100130,6,],O
100130,6,-,O
100130,6,[,O
100130,6,**Location,O
100130,6,(,O
100130,6,un,O
100130,6,),O
100130,6,**,O
100130,6,],O
100130,6,syndrome,O
100130,6,secondary,O
100130,6,to,O
100130,6,Dilantin,B-Drug
100130,6,.,O
100130,6,2,O
100130,6,.,O
100130,6,Status,O
100130,6,post,O
100130,6,craniotomy,O
100130,6,on,O
100130,6,[,O
100130,6,**2109-7-1**,O
100130,6,],O
100130,6,",",O
100130,6,for,O
100130,6,a,O
100130,6,cystic,O
100130,6,cranial,O
100130,6,lesion,O
100130,6,",",O
100130,6,likely,O
100130,6,dysembryoplastic,O
100130,6,angioneural,O
100130,6,epithelial,O
100130,6,lesion,O
100130,6,with,O
100130,6,features,O
100130,6,consistent,O
100130,6,with,O
100130,6,an,O
100130,6,oligodendroglioma,O
100130,6,.,O
100130,6,DISCHARGE,O
100130,6,MEDICATIONS,O
100130,6,:,O
100130,6,Polysporin,B-Drug
100130,6,ophthalmology,O
100130,6,O.U,O
100130,6,.,O
100130,6,q.i.d.,O
100130,6,",",O
100130,6,hydrated,B-Drug
100130,6,Petroleum,I-Drug
100130,6,as,O
100130,6,needed,O
100130,6,",",O
100130,6,Lipitor,B-Drug
100130,6,10,O
100130,6,mg,O
100130,6,p.o,O
100130,6,.,O
100130,6,q.d.,O
100130,6,",",O
100130,6,Nystatin,B-Drug
100130,6,",",O
100130,6,Boost,O
100130,6,t.i.d,O
100130,6,.,O
100130,6,FOLLOW-UP,O
100130,6,:,O
100130,6,1,O
100130,6,.,O
100130,6,Ophthalmology,O
100130,6,[,O
100130,6,**2109-8-20**,O
100130,6,],O
100130,6,",",O
100130,6,at,O
100130,6,12:45,O
100130,6,p.m.,O
100130,6,2,O
100130,6,.,O
100130,6,Primary,O
100130,6,care,O
100130,6,physician,O
100130,6,in,O
100130,6,two,O
100130,6,weeks,O
100130,6,.,O
100130,6,3,O
100130,6,.,O
100130,6,Dermatology,O
100130,6,as,O
100130,6,needed,O
100130,6,.,O
100130,6,DISCHARGE,O
100130,6,NOTE,O
100130,6,:,O
100130,6,PLEASE,O
100130,6,NOTE,O
100130,6,THAT,O
100130,6,THE,O
100130,6,PATIENT,O
100130,6,IS,O
100130,6,ALLERGIC,O
100130,6,TO,O
100130,6,DILANTIN,B-Drug
100130,6,AND,O
100130,6,TEGRETOL,B-Drug
100130,6,GIVEN,O
100130,6,HER,O
100130,6,[,O
100130,6,**Doctor,O
100130,6,Last,O
100130,6,Name,O
100130,6,**,O
100130,6,],O
100130,6,-,O
100130,6,[,O
100130,6,**Location,O
100130,6,(,O
100130,6,un,O
100130,6,),O
100130,6,**,O
100130,6,],O
100130,6,SECONDARY,O
100130,6,TO,O
100130,6,DILANTIN,B-Drug
100130,6,.,O
100130,6,The,O
100130,6,patient,O
100130,6,is,O
100130,6,recommended,O
100130,6,to,O
100130,6,wear,O
100130,6,an,O
100130,6,alert,O
100130,6,bracelet,O
100130,6,which,O
100130,6,indicates,O
100130,6,this,O
100130,6,reaction,O
100130,6,.,O
100130,6,[,O
100130,6,**Name6,O
100130,6,(,O
100130,6,MD,O
100130,6,),O
100130,6,2415**,O
100130,6,],O
100130,6,[,O
100130,6,**Last,O
100130,6,Name,O
100130,6,(,O
100130,6,NamePattern4,O
100130,6,),O
100130,6,3474**,O
100130,6,],O
100130,6,",",O
100130,6,M.D,O
100130,6,.,O
100130,6,[,O
100130,6,**MD,O
100130,6,Number,O
100130,6,(,O
100130,6,1,O
100130,6,),O
100130,6,3475**,O
100130,6,],O
100130,6,Dictated,O
100130,6,By,O
100130,6,:,O
100130,6,[,O
100130,6,**Last,O
100130,6,Name,O
100130,6,(,O
100130,6,NamePattern4,O
100130,6,),O
100130,6,40425**,O
100130,6,],O
100130,6,MEDQUIST36,O
100130,6,D,O
100130,6,:,O
100130,6,[,O
100130,6,**2109-9-3**,O
100130,6,],O
100130,6,12:59,O
100130,6,T,O
100130,6,:,O
100130,6,[,O
100130,6,**2109-9-3**,O
100130,6,],O
100130,6,12:58,O
100130,6,JOB,O
100130,6,#,O
100130,6,:,O
100130,6,[,O
100130,6,**Job,O
100130,6,Number,O
100130,6,99931**,O
100130,6,],O
100130,6,[,O
100130,6,**Name6,O
100130,6,(,O
100130,6,MD,O
100130,6,),O
100130,6,**,O
100130,6,],O
100130,6,[,O
100130,6,**Name8,O
100130,6,(,O
100130,6,MD,O
100130,6,),O
100130,6,**,O
100130,6,],O
100130,6,",",O
100130,6,M.D,O
100130,6,.,O
100130,6,(,O
100130,6,cclist,O
100130,6,),O
